In situ antitumor vaccination: Targeting the tumor microenvironment. Issue 7 (6th February 2020)

• Record Type: Journal Article
• Authors: Li, Hanwen; Yu, Jiayun; Wu, Yongyao; Shao, Bin; Wei, Xiawei
• Is Part Of: Journal of cellular physiology. Volume 235:Issue 7/8(2020)
• Page Start: 5490
• Page End: 5500
• Publication Date: 2020-02-06
• Subjects: immunotherapy -- intratumoral injection -- tumor microenvironment; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.29551
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Tumor microenvironment is known to play important roles in tumor progression. Many therapies, targeting the tumor microenvironment, are designed and applied in the clinic. One of these approaches is in situ antitumor therapy. This way, bacteria, antibodies, plasmid DNA, viruses, and cells are intratumorally delivered into the tumor site as "in‐situ antitumor vaccine, " which seeks to enhance immunogenicity and generate systemic T cell responses. In addition, this intratumoral therapy can alter the tumor microenvironment from immunosuppressive to immunostimulatory while limiting the risk of systemic exposure and associated toxicity. Contemporarily, promising preclinical results and some initial success in clinical trials have been obtained after intratumoral therapy. Abstract : Intratumoral therapies that target the tumor microenvironment are showing promise in oncology and have given rise to many clinical benefits.In this article, in situ antitumor vaccinations targeting the tumor microenvironment were reviewed.